We are pleased to introduce the new members of the EMBO Molecular Medicine Advisory Board. Members of the Board provide scientific advice to the editors for which we are very grateful. A full list of the Advisory Board is also available.
Should you wish to contact a Board member about EMBO Molecular Medicine, please do so through the Editorial Office: email@example.com
University of Napoli "Federico II" and Principal Investigator at TIGEM, Napoli, Italy
Prof. Alberto Auricchio is Associate Professor of Medical Genetics at the University of Napoli "Federico II" and Principal Investigator at TIGEM, Napoli. His group has contributed to one of the first demonstrations that retinal gene therapy using AAV vectors is safe and effective in humans. Prof. Auricchio's group is currently aiming at expanding AAV cargo capacity for gene therapy of blinding conditions due to mutations in large genes. In addition, the group of Prof. Auricchio is developing AAV liver gene therapy for mucopolysaccharidosis VI and is coordinating an EU consortium to test this approach in a phase I/II clinical trial.
WELBIO, Interdisciplinary Research Institute, Université Libre de Bruxelles, Brussels, Belgium
Prof. Cédric Blanpain is full professor and WELBIO investigator at the Université Libre de Bruxelles, Belgium. His group studies the role of stem cells (SCs) during development, homeostasis and cancer. Prof. Blanpain demonstrated the key role of Mesp1 during the specification of cardiovascular progenitors, identified the cellular origin of Merkel cells and the mechanisms by which hair follicle SCs resist DNA damage-induced cell death. Using lineage-tracing approaches, he uncovered new SC populations in the epidermis, mammary gland and the prostate, as well as the cells originating the two most frequent skin cancers. He also recently developed new methods to investigate cancer stem cells within their natural environment and identified new intrinsic and extrinsic regulators of skin cancer SCs.
University of Cambridge, Cancer Research UK Cambridge Research Institute, UK
Professor Caldas holds the Chair of Cancer Medicine at the University of Cambridge since 2002. He heads the Breast Cancer Functional Genomics Laboratory at the Cancer Research UK Cambridge Institute. His research focus is in the functional genomics of breast cancer and its biological and clinical implications. His laboratory recently completed the analysis of the largest genomic and transcriptomic study of breast cancers, the miRNA profiling of 1,300 of the same tumors uncovering a new role for miRNAs as modulators of the immune response in a subset of breast cancers and co-lead seminal studies to define the clonal heterogeneity of triple negative breast cancers, patterns of whole-genome ER binding in primary tumors, established ctDNA as a monitoring biomarker a liquid biopsy to unravel therapy resistance. More recently his laboratory has been developing the use of patient-derived tumor cells as a model system for breast cancer.
Children’s Medical Center Research Institute, UT Southwestern Medical Center, Dallas TX, USA
Prof. Ralph DeBerardinis is Associate Professor and the Joel B. Steinberg, M.D. Chair in Pediatrics at the Children’s Medical Center Research Institute at UT Southwestern Medical Center, Dallas Tx, USA. He is a medical geneticist with clinical and research interests in the role of altered metabolic states in disease. Ralphs’s laboratory uses metabolomics, metabolic flux analysis, and molecular imaging to probe metabolic pathway utilization in two classes of human disease: cancer and childhood inborn errors of metabolism. The research group’s goal is to capitalize on altered metabolic states to better understand pathophysiology and to develop new ways to detect, monitor and treat these conditions.
University Hospital Freiburg & German Cancer Research Center (DKFZ), Heidelberg, Germany
Prof. Sven Diederichs is a Full Professor of Cancer Research in Thoracic Surgery of the University Hospital Freiburg as well as the Head of the Division "RNA Biology & Cancer" at the German Cancer Research Center (DKFZ) in Heidelberg. His research is focused on the functional characterization of long non-coding RNAs (lncRNAs) at the cellular and molecular level. Best known for his discovery of the lncRNA MALAT1 and its active role in lung cancer metastasis, he now studies lncRNAs, ribonucleoprotein complexes as well as the impact of mutations outside of the coding region in lung and liver cancer.
Institute of Lung Biology and Disease, Ludwig-Maximilians-University, Munich, Germany
Professor Oliver Eickelberg is Chairman of the Comprehensive Pneumology Center/Institute of Lung Biology and Disease, Ludwig-Maximilians-University and Helmholtz Zentrum München and Vice Chairman, German Center for Lung Research (DZL). Professor Eickelberg studies the mechanisms of structural remodelling of the lung in chronic lung diseases, such as Idiopathic Pulmonary Fibrosis (IPF) or Chronic Obstructive Pulmonary Disease (COPD). His research focuses on characterising and regenerating functional lung tissue in disease, by focusing on fibrotic signalling pathways (e.g. TGF-beta), epithelial-mesenchymal interaction, and dynamics of extracellular matrix composition. His work aims at translating these findings to clinical practice by uncovering new biomarkers and therapeutic regimens.
The Prostate Centre at VGH Urologic sciences Vancouver, British Colombia, Canada
Prof. Martin Gleave is a Distinguished Professor and Vice Chair of the Department of Urologic Sciences at the University of British Columbia (UBC) Canada, Director of the Vancouver Prostate Center, and a British Columbia Leadership Chair. Prof. Gleave¹s research characterizes molecular mechanisms mediating treatment resistance in cancer, focusing on stress-activated adaptive responses that drive acquired treatment resistance, and designing rational combination co-targeting strategies to create conditional lethality and improve cancer control. He founded OncoGenex Pharmaceuticals to develop inhibitors targeting cytoprotective chaperones clusterin (OGX-011) and Hsp27 (OGX-427) now in Phase II and III trials in several cancers.
Gene Center and Department of Biochemistry, Ludwig-Maximilians-Universität Munich, Germany
Prof. Veit Hornung is chair of Immunobiochemistry at the Gene Center of the Ludwig-Maximilians-Universität Munich. Dr. Hornung’s research focuses on the mechanisms of non-self recognition by the innate immune system and its functional consequences in microbial infection as well as sterile inflammation. His group was involved in the identification and characterization of several receptor molecules, their ligands, and their downstream signaling cascades, most importantly in the field of nucleic acid recognition as well as in the inflammasome system. More recently, his group has focused its efforts on the dissection of innate signaling pathways in human immune cells using genome engineering technologies.
Department of Medical Biophysics, University of Toronto, Canada
Prof. Robert Kerbel is Canada Research Chair in Tumor Biology, Angiogenesis, and Antiangiogenic Therapy and a professor in the Dept. of Medical Biophysics at the University of Toronto. His main interest has been to devise new cancer treatment strategies having both improved efficacy and reduced toxicity. A number of his findings are now being evaluated in clinical trials, particularly in breast, ovarian, colorectal, and various pediatric cancers. His contributions include the development of improved preclinical models involving early stage or advanced metastatic disease for experimental therapeutic investigations and elucidating mechanisms of acquired antiangiogenic drug resistance.
INSERM, U848, Villejuif, and Université Paris Descartes, Sorbonne Paris Cité, Paris, France
Prof. Guido Kroemer is best known for the discoveries that the permeabilization of mitochondrial membranes constitutes a decisive step in programmed cell death, that autophagy is a cytoprotective mechanisms that if induced at the whole-body level increases lifespan, and that antineoplastic therapies are only successful if they stimulate anticancer immune responses. He received the Descartes Prize of the European Union, the Carus Medal of the Leopolidina, the Dautrebande Prize of the Belgian Royal Academy of Medicine, the Léopold Griffuel Prize of the French Association for Cancer Reseach, as well as a European Research Council Advanced Investigator Award. He is the director of the Paris Alliance of Cancer Research Institutes and of the Labex Immuno-Oncology.
Group leader in VIB (Flanders Institute for Biotechnology) and professor at the University of Ghent, Belgium
Claude Libert is a trained geneticist. His major research interest is acute inflammation such as sepsis, and the cross-talk between several important players in inflammation, with a focus on TNF, IFN, matrix metalloproteinases and glucocorticoids.
Center for Systems Biology, Massachusetts General Hospital, USA
Dr. Nahrendorf is an associate professor at Harvard Medical School and director of the Mouse Imaging Program at the Center for Systems Biology at Massachussetts General Hospital. His laboratory focuses on the cellular and molecular processes in atherosclerosis and after myocardial infarction, using the entire spectrum of imaging modalities, including MRI, nuclear, and optical imaging techniques, with a special interest in multimodal imaging. These technologies are embedded in a biologically driven research program that aims at a systematic understanding of inflammation at a basic level while keeping a rigorous translational perspective.
Department Cell Mol Medicine, KU Leuven, Belgium
Bernd Nilius is Emeritus Professor at KU Leuven (Belgium), where he worked until 2010 as Full Professor of Physiology and from 2005-2010 as Director of the "Center of Excellence: TRP Channels". He discovered cardiac T-type Ca2+ channels, volume-regulated anion channels in vascular endothelium and has initiated a very successful research on TRP cation channels. His work has strong connections to the role of ion channels in hereditary and aquired diseases (channelopathies), which led e.g. to the discovery of the role of TRPV4 channels in skeletal dysplasias and neuropathies. He is member of several Academies, of EMBO and has received some prestiguos prizes such as the Dautrebade award presented by the Queen of Belgium.
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
Prof. Kornelia Polyak is Professor of Medicine at the Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA USA. Prof. Polyak's laboratory is dedicated to the molecular analysis of human breast cancer. The goal is to better understand the molecular evolution of human breast tumors and to use this information to improve the clinical management of breast cancer patients. The areas of major focus of the her laboratory are currently: better understanding the clinical and biological relevance of tumor heterogeneity, the role of microenvironment in tumor progression and therapeutic responses, molecular and cellular mechanisms of breast cancer risk, the role of epigenetic mechanism in breast cancer subtypes and heterogeneity, and new therapeutic targets in breast cancer.
Molecular Neurology Research Program, University of Helsinki and Helsinki University Central Hospital, Finland
Prof. Anu Suomalainen-Wartiovaara is the Sigrid Jusélius Professor of Clinical Molecular Medicine at University of Helsinki and Director of Molecular Neurology Research Program, and Chief Physician at Helsinki University Central Hospital, Finland. Her research group is part of the FinMIT centre of excellence of the Academy of Finland, and is located at Biomedicum-Helsinki. Anu’s work is focused on understanding the molecular consequences of mitochondrial dysfunction, and applies the knowledge obtained from patients and disease models to develop diagnostic strategies and treatments for mitochondrial diseases, and for common metabolic dysfunctions, including aging-related degenerative disorders.